Progressive Multifocal Leukoencephalopathy (PML)

---

🔊 Listen to Post

---

What Is Progressive Multifocal Leukoencephalopathy (PML) and its connection with Multiple Sclerosis (MS)

Progressive Multifocal Leukoencephalopathy (PML) is a rare but serious brain infection caused by the JC virus, a common virus that typically remains dormant in most people. However, in individuals with weakened immune systems, it can reactivate, leading to PML—a disease that damages the white matter in the brain and disrupts communication between brain cells. This infection can lead to severe neurological symptoms and is often life-threatening, with rapid progression and limited treatment options. Among the populations at risk for PML are people with Multiple Sclerosis (MS), particularly those undergoing certain treatments that suppress immune function.

Understanding Progressive Multifocal Leukoencephalopathy (PML)

PML is caused by the JC (John Cunningham) virus, a typically harmless virus that about 70–90% of the population carries without issue. For most, the immune system keeps this virus in check, often in the kidneys, and it remains asymptomatic throughout life. However, when immune function is severely compromised—such as in cases of HIV/AIDS, cancer treatments, or certain immunosuppressive therapies—the JC virus can become reactivated, cross the blood-brain barrier, and infect the brain. This results in demyelination, a process where the protective myelin sheath surrounding nerve cells is damaged, leading to white matter lesions and severe neurological impairment.

Symptoms of PML include:

• Weakness or paralysis in parts of the body
• Visual disturbances
• Cognitive impairments
• Difficulty speaking or understanding language
• Seizures

The symptoms vary depending on which areas of the brain are affected, and the disease can progress rapidly, leading to severe disability or death if not managed.

The Connection Between PML and Multiple Sclerosis (MS)

Multiple Sclerosis (MS) is an autoimmune disease where the body’s immune system mistakenly attacks the central nervous system, leading to inflammation, demyelination, and damage to nerve fibers. Many MS patients are prescribed immunomodulatory drugs to manage inflammation and prevent MS relapses. However, certain MS medications, particularly those that alter immune function, have been linked to an increased risk of PML.

The connection lies in the immune-suppressing or modulating effects of some MS treatments. By altering the immune system to reduce MS symptoms, these medications may inadvertently create a favorable environment for the JC virus to reactivate, leading to PML.

MS Medications and PML Risk

The following MS medications are particularly associated with PML risk:

1. Natalizumab (Tysabri): One of the most effective drugs for MS, Natalizumab works by inhibiting immune cells from entering the brain and spinal cord, thus reducing inflammation. However, this also reduces the brain’s defenses against infections like PML. The risk of PML increases with longer treatment durations, especially in patients who test positive for the JC virus antibody.
2. Fingolimod (Gilenya): This oral medication reduces the movement of immune cells from lymph nodes, limiting their ability to cause inflammation in the CNS. Though the risk of PML with Fingolimod is lower than with Natalizumab, several cases have still been reported, particularly in those with prior exposure to immunosuppressive drugs.
3. Dimethyl Fumarate (Tecfidera): While the PML risk associated with Dimethyl Fumarate is lower, cases have occurred, especially in patients with low lymphocyte counts, a condition that weakens the immune system’s ability to fight infections.
4. Ocrelizumab (Ocrevus): A newer treatment, Ocrelizumab, depletes specific B cells, which play a role in the immune response. Although the risk of PML with Ocrelizumab is considered lower, it’s still a potential risk, especially in those with JC virus positivity.

Who Is at Higher Risk?

PML risk factors among MS patients include:

• JC Virus Antibody Positivity: Testing positive for the JC virus antibody indicates prior exposure to the virus, which raises the risk of reactivation.
• Previous Immunosuppressive Therapy: Patients who have used immunosuppressants for an extended period are at a higher risk.
• Duration of Treatment: The longer the treatment duration with certain MS drugs, such as Natalizumab, the higher the risk of PML.
• Low Immune Cell Count: Reduced immune cells, particularly lymphocytes, are another risk factor, as these cells are essential for controlling infections.

Symptoms of PML in MS Patients

The symptoms of PML can sometimes overlap with MS symptoms, making diagnosis challenging. However, any new or worsening neurological symptoms, such as increased difficulty with movement, coordination, speech, or cognition, may be a red flag for PML and should prompt immediate medical attention. MRI scans and lumbar puncture tests (to detect JC virus in the cerebrospinal fluid) are often used to diagnose PML.

Preventing and Monitoring for PML in MS Patients

For MS patients on treatments associated with PML risk, regular monitoring is essential. Steps to reduce risk include:

• JC Virus Antibody Testing: This test can help predict PML risk. Patients who test positive for JC virus antibodies may consider alternative treatments.
• Regular Blood Tests: Monitoring lymphocyte counts helps detect any signs of immune suppression.
• Frequent MRI Scans: Regular MRI scans help detect any early signs of brain changes related to PML, allowing for earlier intervention if needed.
• Risk-Benefit Assessment: Doctors and patients should carefully weigh the risks and benefits of immunosuppressive drugs, particularly if other treatment options are available.

Treatment Options for PML

Treating PML is challenging, as there is no cure. Management typically involves stopping the immunosuppressive therapy to allow the immune system to recover and fight the JC virus. For instance, patients on Natalizumab may undergo plasma exchange to clear the drug from their system more quickly. Some experimental therapies, such as immunotherapy, are being explored, but the prognosis remains guarded.

Conclusion

Progressive Multifocal Leukoencephalopathy (PML) is a severe, life-threatening condition that poses a particular risk for MS patients using immunosuppressive therapies. Awareness of the risk factors, regular monitoring, and open communication with healthcare providers are essential for MS patients considering or currently using these medications. By staying informed and vigilant, patients can make safer, more informed choices about their treatment options and work closely with their medical team to minimize PML risk while managing MS effectively.

Final Note From The Author: I had my annual routine consultation today and received some concerning news—my neurologist is considering putting me on Ocrelizumab (Ocrevus). Given that I’ve been living with Multiple Sclerosis for the past eight years and was initially treated with Alemtuzumab, I decided to do some research on this new option. My relapses have become more frequent, so they’re exploring alternatives, though they’ll need to review my MRI results before making a final decision. Ocrelizumab is an infusion treatment given every six months, which sounds manageable, but I’m particularly concerned about the risk of contracting Progressive Multifocal Leukoencephalopathy (PML), a rare but serious infection linked to some MS treatments. If the risk of PML is significant, I may consider refusing treatment altogether, as I’m wary of the potential complications.

---

---